L'interopérabilité est une des caractéristiques requises pour les entreprises évoluant dans un marché globalisé à la concurrence croissante et complexe. Dans la dernière décennie, l'interopérabilité des entreprises a été développée et prescrite par différents types de cadres, de méthodes et de techniques. Cependant, le développement de l'interopérabilité n'est pas encore assez mature pour être considéré en tant que science à part entière. Par ailleurs, il ne cesse d'évoluer en fonction des besoins des entreprises,de leurs environnements et des différents secteurs d’activité. Aujourd'hui, l'environnement s’organise en réseaux multipleet provoque d’imprévisibles situations liées à leurs dynamiques (création, modification, résilience). Ainsi l’interopérabilité durable devient une dimension nouvelle de recherche pour l'interopérabilité des systèmes d'entreprise et de leurs domaines d'applications. Dans l'interopérabilité durable, l'interopérabilité d'entreprise dynamique est l'un des thèmes focaux. Cette approche dynamique, également appelée « fédérée », est originaire du cadre d'interopérabilité de l'Entreprise proposée dans le Réseau d’Excellence (NoE)INTEROP. Il vise à donner la capacité aux entreprises d’établir une interopérabilité à la volée sans connaissance préalable des informations à échanger. Cette thèse présente l'état actuel des travaux qui se rapprochent du développement de l'interopérabilité des entreprises « fédérés » en dynamique. Ces travaux de thèse mettent tout d’abord en évidence l’intérêt de la redécouverte de modèles à partir d’un système existant avant de concevoir un futur système. Une méthodologie de réverse engineering dirigée par les modèles et basée sur la norme de simulation distribuée HLA est proposée pour concevoir et développerpar l'approche fédérée d'interopérabilité le futur système d’information de l’entreprise. La phase de mise en œuvre réutilise les concepts d’interopérabilité issusde la simulation distribuée pour faciliter et coordonner la communication entre les systèmes d'information distribués hétérogènes des entreprises en combinant avec les dernières orientation service actuelle du web. La plate-forme tend ainsi à satisfaire les attentes de la dernière version du standard de l'architecture de haut niveau HLA 1516 Evolved. Ce cadre propose donc un cycle complet de développement pour qui a l'intention de réutiliser un système d'information existant sans recoder ex-nilo, mais en l’adaptant aux nouvelles exigences de la dynamique d'interopérabilité. / Interoperability is one of the requisite features for existing enterprises in the increasing competitive and complex global market. In the last decade, enterprise interoperability has been developed and prescribed by various kinds of frameworks, methods, and techniques. However interoperability development is still not mature enough to become a science. Meanwhile, it keeps evolving according to different business requirement and market environment. Nowadays, networked environment causes unpredictable dynamical situations, thus sustainable interoperability becomes a new research dimension in the interoperability of enterprise systems and applications domain. In the sustainable interoperability, enterprise interoperability dynamics is one of the focal topics. This dynamic approach also called federated is originated from Enterprise Interoperability Framework of INTEROP NoE, which aims to establish interoperability on the fly. This thesis presents current state on federated approaches to develop enterprise interoperability dynamics. Based on this study, a reversible model driven and HLA based methodology is proposed for achieving federated approach for Enterprise Interoperability. It reuses distributed simulation interoperability concepts to facilitate and coordinate the communication between heterogeneous distributed information systems of the enterprises. The platform is complaint with the latest version of the High Level Architecture (HLA) that is a distributed communication standard. This framework is also proposing a development lifecycle that intends to reuse existing information systems without recoding them but by adapting them to the new requirements of interoperability dynamics.

Les lymphocytes T cytotoxiques (CTLs) dirigés contre le VIH jouent un rôle essentiel dans la défense anti-virale. L’identification des facteurs impliqués dans la variabilité de ces réponses est indispensable à la mise au point de vaccins efficaces.Nous avons focalisé notre travail sur deux facteurs potentiellement impliqués dans la reconnaissance du virus par le HLA : le sous-type viral et la qualité de l’apprêtement antigénique. L’extrême variabilité du virus avec à ce jour 11 sous-types et 48 formes recombinantes (CRFs) circulant au sein de populations au typage HLA hétérogène implique un polymorphisme important avec des mutations d’échappement multiples.Nos résultats montrent que dans la population Vietnamienne infectée par le VIH, le CRF01_AE prédomine largement et que l’affinité pour la molécule HLA des épitopes CTL classiquement décrits dans les sous-types B est drastiquement diminuée, ce qui favorise l’échappement de ce sous-type viral au système immunitaire.Par ailleurs, nous avons montré que l’apprêtement des épitopes CTL dépend du type de cellule impliquée, les monocytes se caractérisant par une capacité de présentation significativement plus forte à l’origine d’une réponse CTL plus efficiente comparativement aux lymphocytes T CD4 . Des tests de dégradation in vitro ont démontré que la stabilité intracellulaire des épitopes est hautement variable, dépendante de la séquence en acides aminés et contribue à l’optimisation de la réponse CTL.L’ensemble de ces résultats indiquent que, au delà de l’affinité pour le HLA ou le TCR et des facteurs d’épuisement cellulaire, la réponse CTL peut aussi être modulée par le sous-type viral et l’apprêtement antigénique. / HIV-specific cytotoxic T lymphocytes (CTLs) play a critical role for clearance of virus-infected cells and induction of these cells is a necessary component of any successful vaccine strategy against AIDS. Therefore, identification of the factors defining and modulating the efficiency of these protective responses are urgently needed. We focused our study on two factors potentially involved in HLA recognition: HIV-1 sub-type and antigen processing.The extreme variability of the virus with to date 11 HIV-1 subtypes and 48 circulant recombinant forms (CRFs) circulating worlwide among heterogeneous populations imply high polymorphism and different mutational escape patterns.We demonstrate that among the HIV-1 infected Vietnamese population where the CRF01_AE is largely predominant, the HLA binding of known CTL epitopes is strongly reduced compared to the subtype B due to intraepitopic mutations, facilitating immune evasion of these viral strains.Moreover, we show that the presentation of adequate amounts of epitopes leading to CTL recognition depends on the subset cells involved in the antigen processing, monocytes having a significantly higher and more efficient proteolytic activity. Using in vitro degradation assays, we measured the intracellular HIV-1 epitope stability and demonstrated that this factor is highly variable, sequence dependent and also contributes to a more efficient presentation.Together, these data indicate that, besides HLA and TCR binding and exhaustion factors, HIV-1 CTL recognition can also be modulated by the viral sub-type and the antigen processing machinery.

Background: Type of 1 diabetes (T1D) is an autoimmune disease in which the cells of immune system attack the β-cells of pancreas. Consequently, destroyed β-cells do not produce insulin to reduce blood sugar levels. This disease is very complex, the pathogenesis is contributed by both genetic factors and environmental factors. In recent years, the number of individuals with T1D is increasing worldwide. Aims: The aim of this thesis was to investigate whether it is possible to predict T1D based on the expression profile of BACH2, CDC20, IGLL3P, EIF3A and TXNDC5 genes , which are involved in the development of immune system cells and insulin production. Another aim was to compare the expression of selected genes in children, in which the first detection of the disease may be done, and adults who suffer from prolonged T1D. The final goal was to compare the expression of individual selected genes in the HLA risk alleles DR04, DR03, DQA*05:01 a DQB*03:02. Methods: The DNA and RNA of patients with T1D and healthy individuals was isolated from blood. DNA was used to HLA genotyped. Isolated RNA was reverse transcribed into cDNA and then used in real-time PCR to determine the relative levels of gene expression. Conclusion: Significant results were obtained when the expression of BACH2, CDC20 and TXNDC5 genes...

La polyarthrite rhumatoïde (PR) est le rhumatisme inflammatoire chronique le plus fréquent avec une prévalence mondiale qui varie selon les pays mais se situe aux alentours de 0,5% dans le monde. La PR est caractérisée par une atteinte articulaire souvent bilatérale et symétrique, évoluant par poussées inflammatoires, une production d'auto-anticorps, une destruction du cartilage et de l'os entrainant des déformations. La PR peut survenir à tous les âges mais apparaît le plus souvent entre 40 et 60 ans, avec une forte prédominance féminine (3 : 1). Il existe des variations géographiques au sein d'un même continent ou d'un même pays en raison de facteurs environnementaux, immunologiques mais aussi génétiques. Depuis bientôt 40 ans, l’implication du gène HLA-DRB1 est connue. Les études à grande échelle sur tout le génome ont permis d’identifier 110 nouveaux polymorphismes qui n’expliquent qu’une partie de la composante génétique de la PR. Ces études ont été principalement menées dans les populations d’Amérique du Nord, d’Asie ou d’Europe du Nord. L’objectif de ma thèse était donc d’étudier des facteurs génétiques de prédisposition à la PR 1) codant pour des microARNs ou mARNs, 2) dans deux populations jusqu’ici peu ou pas étudiées, et 3) portés par le chromosome X.Pour cela, j’ai travaillé sur deux ethnies différentes (Tunisienne et Française) afin d’effectuer une étude d’association « cas-contrôle » via une approche « gènes candidats». J’ai genotypé 3 polymorphismes (SNPs) sur le locus Xq28, et 2 SNPs sur le gène REL et quantifié le niveau d’expression de 13 micro-ARNs (miR-363, miR-106a, miR-20b, miR-188, miR-92a, miR-532, miR-652, miR-221, miR-222, miR-223, miR-98, let-7f miR-718 et miR-3202) situés sur le chromosome X. J’ai également évalué les composantes HLA et l’épitope partagé (EP) dans ces deux populations. J’ai effectué une analyse des haplotypes et du degré de déséquilibre de liaison (LD) pour chaque locus. Enfin j’ai validé mes résultats grâce à des méta-analyses.Mes résultats sur un échantillon cas/témoins de 995 individus montrent que les locus Xq28 et REL sont fortement associés à la PR chez les femmes Tunisiennes et Françaises, avec des différences entre ces deux populations. Les résultats des allèles du complexe HLA-DRB1 pourraient expliquer ces différences puisque ce ne sont pas les mêmes allèles HLA-DRB1 qui prédominent dans les deux populations. Parmi les 11 micro-ARNs étudiés, deux ne sont pas détectables (miR-718 et miR-3202) dans les PBMCs des patients atteints de PR, cinq (miR-221, miR-222, miR-223, miR-106a, miR-98) montrent une différence statistique d’expression entre les femmes contrôles et les femmes PR, et 6 (let-7f, miR-188, miR-652, miR-20b, miR-363, miR-92a) ne montrent aucune différences entre les deux groupes. Le cluster miR-221-222 montre une corrélation avec le génotype (AA+AG) de SNP rs3761548 et (AG+GG) versus (AA) et rs2223356 du gène FoxP3 chez les patients atteints de PR seulement avec une stratification en fonction du sexe.En conclusion, cette étude de 3 types de facteurs génétiques de prédisposition à la PR apporte un éclairage nouveau aux précédentes études Asiatiques ou d’Europe et d’Amérique du Nord, mettant en évidence des différences ethniques et géographiques. Des études de génomique fonctionnelle et sur de larges cohortes masculines seront nécessaires pour une meilleure compréhension de la physiopathologie de la PR et de l’importance du chromosome X dans cette maladie. Par ailleurs, le rôle des micro-ARNs en tant que facteurs génétiques de prédisposition de la PR reste peu étudié et mérite de futures explorations. / Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease with a worldwide prevalence that varies by country but is around 0.5% worldwide. RA is characterized by a bilateral and symmetrical joint disease, relapsing inflammation, production of auto-antibodies, cartilage destruction and bone causing deformations. RA can occur at any age, however, it appears most often between 40 and 60 years, with a strong female predominance (3: 1). There are geographical variations within the same continent or in the same country because of environmental factors, immunological but also genetical reasons. For nearly 40 years, the involvement of the HLA-DRB1 gene is known. Large-scale studies of the genome have identified 110 new polymorphisms (SNPs) that explain only a part of the genetic component of RA. These studies were mainly conducted in North American, Asian and North European populations. The aim of my thesis was to study genetic factors of susceptibility to RA 1) encoding microRNAs and mRNAs, 2) in two unstudied populations, and 3) with a specific focus on the X chromosome.For that, I worked on two different ethnicities (Tunisian and French) to conduct a "case-control" study of association via a "candidate gene" approach. I have genotyped 3 SNPs on the Xq28 locus (rs1059702, rs1059703, rs13397) and two SNPs on the REL gene , and quantified the expression level of 11 micro-RNAs (has_Mir-223, has_Mir-363, has_Mir-106a, 20b-has_Mir, has_Mir-188, has_Mir-92a, has_Mir-532, has_Mir-652, has_Mir-221, has_Mir -222, has_Mir-223, has_Mir-98 and let-7f) located within the X chromosome. I also assessed the HLA components and the shared epitope (SE) in these two populations. I performed a haplotype analysis and a linkage disequilibrium (LD) study for each locus. Finally I validated my results through a Meta-analysis.My results on a case/control sample of 995 individuals show that the Xq28 locus and REL locus are strongly associated with RA in both Tunisian and French women, with however differences between the two populations. The results of the HLA-DRB1 alleles might explain these differences since different HLA-DRB1 alleles predominate in each population. In overall our analysis showed that among the 11 studied X-linked miRNAs, two are not detectable (miR-718 and miR-3202) in PBMCs of RA patients, five (miR-221, miR-222, miR-223, miR-106a, miR-98) show a statistical difference between controls and RA women, and 6 (let-7f, miR-188, miR-652, miR-20b, miR-363, miR-92a) show no differences between controls and RA women. MiR-222 and miR-221 was statically correlation with (AA+AC) versus (CC) FoxP3 SNP rs3761548 and (AG+GG) versus (AA) FoxP3 SNP rs2223356 in RA patients only with gender stratification.In conclusion, this study focusing on three types of genetic predisposition to RA sheds new light on the previous studies from Asia, Northern Europe and America, highlighting ethnical and geographical differences. Functional genomic studies and large male cohorts will be needed for a better understanding of the pathophysiology of RA and to study the importance of the X chromosome in this disease. Moreover, the role of micro-RNAs as genetic factors of RA remains under-studied and needs further exploration.

Orientadores: Lilian Maria de Castilho, Jeane Eliete Laguila Visentainer / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-24T13:14:12Z (GMT). No. of bitstreams: 1 Guelsin_GlauciaAndreiaSoares_D.pdf: 3524338 bytes, checksum: 77312cdc47d244e00235a67d7f52c666 (MD5) Previous issue date: 2014 / Resumo: A síndrome mielosplásica (SMD) correponde a um grupo de distúrbios clonais heterogêneos decorrente de um defeito intrínseco das células progenitoras hematopoéticas, resultando em insuficiência da medula óssea, desencadeando anemia com dependência de transfusões sanguíneas e infecções decorrentes da neutropenia. Embora a terapia transfusional seja segura, muitos desses pacientes correm risco de complicações relacionadas à sobrecarga de ferro e à aloimunização contra antígenos de grupos sanguíneos, que muitas vezes dificulta a busca de sangue compatível para esses pacientes, além estar associada a reações hemolíticas transfusionais tardias e formação de auto-anticorpos. A compatibilidade para antígenos Rh e K tem sido utilizada na tentativa de reduzir a formação de anticorpos em pacientes que recebem transfusões crônicas, mas a fenotipagem estendida, incluindo os antígenos Fya e Jka, também tem sido recomendada. Este estudo teve como objetivos avaliar o perfil transfusional dos pacientes com SMD, propor um protocolo de compatibilidade molecular para seleção de sangue fenótipo compatível e avaliar uma possível associação dos alelos HLA com a susceptibilidade ou proteção a aloimunização eritrocitária. Foram analisados 61 pacientes portadores de SMD, sendo 18 pacientes não transfundidos e 43 pacientes submetidos à terapia transfusional com e sem formação de anticorpos. Realizamos genotipagem para os alelos de grupos sanguíneos RHD, RHCE, FY, DO, CO, DI, SC, GYPA, GYPB, LU, KEL, JK e LW e para os alelos HLA classe I e classe II nas amostras dos pacientes e comparamos os resultados com grupos- controle. Com relação ao perfil transfusional dos pacientes estudados, a maioria recebe transfusões sanguíneas regulares e 44% encontra-se aloimunizada. Os principais aloanticorpos detectados foram contra antígenos Rh e K. Verificamos que a genotipagem é superior a fenotipagem para determinação dos antígenos de grupos sanguíneos e que a compatibilidade molecular para Rh e K seria suficiente para evitar a aloimunização eritrocitária na maioria dos pacientes. Nossos resultados também mostraram uma associação entre o alelo HLA-DRB1*13 e a proteção à aloimunização contra antígenos de grupos sanguíneos em pacientes com SMD / Abstract: The myelodysplastic syndrome (MDS) is a group of heterogeneous clonal disorder caused by an intrinsic stem cell defect with propensity to the bone marrow failure that results in the transfusion dependence and neutropenic infection. Although blood transfusion is generally safe, many of those patients are at risk of transfusion-related complications such as iron overload and RBC alloimmunization that often makes finding compatible RBC products difficult and is also associated with delayed hemolytic transfusion reactions (DHTRs) and autoantibody formation. Matching for Rh and K antigens has been used in an attempt to reduce antibody formation in patients receiving chronic transfusions but an extended phenotyping matching including Fya and Jka antigens has also been recommended. This study was aimed to identify the transfusion profile of the patients with myelodysplastic syndrome (MDS), an efficient transfusion protocol of genotype matching and a possible association of HLA class alleles with susceptibility or protection to RBC alloimmunization. We evaluated 61 patients with MDS, 18 not transfused and 43 undergoing transfusion therapy with and without antibody formation. We performed genotyping for RHD, RHCE, FY, DO, CO, DI, SC, GYPA, GYPB, LU, KEL, JK e LW and for HLA class I and class II alleles in the patient DNA samples and compared the results with a control group. We verified that the majority of patients have regular transfusions and 44% are alloimmunized to RBC antigens. Blood group genotyping was superior to phenotyping to determine the antigen profile in those patients and molecular matching for Rh and K would be enough for most of the patients. Our results also showed a significant association of HLA-DRB1*13 with protection to RBC alloimmunization in patients with MDS / Doutorado / Clinica Medica / Doutora em Clínica Médica

Introduction: Recent findings about the pathogenesis of glaucoma have already demonstrated the presence of some specific autoimmune mechanisms. It has also been shown that autoimmune diseases often manifest in co-occurrence, such as celiac disease and type 1 diabetes mellitus or psoriasis. This association can be explained by sharing some of the risk variants of HLA molecules class II. Considering glaucoma an autoimmune disease, the question raises how the glaucoma genetic risk factors affect the phenotype of another autoimmune disease or vice versa, whether genetic risk variants associated for example with celiac disease can affect the glaucoma phenotype. Aims: The aims of this study were to i) identify possible genetic risk markers associated with the development of glaucoma, based on the available literature, and to map their occurrence among members of a three-generation family suffering from glaucoma and multiple autoimmune diseases, ii) find carriers of HLA-DQ2/DQ8 among the members of the same family, iii) verify whether an individual's genotype correlates with his/her phenotype, and iv) determine the potential effect of specific HLA alleles on the glaucoma phenotype. Material and methods: This study used DNA samples derived from 34 members of a three-generation family, in which coeliac...

In einer Vielzahl von Arbeiten konnten anti-inflammatorische Eigenschaften von Ethylpyruvat (EP) aufgezeigt werden. An verschiedenen Modellen der Sepsis, des hämorrhagischen Schocks, von Verbrennungsschäden, des Apoplex oder der Ischämie und Reperfusion wurde bei der Behandlung mit EP ein protektiver Effekt sowie eine verminderte Produktion von pro-inflammatorischen Zytokinen nachgewiesen. Als biochemische Grundlage wurde die Interaktion von EP mit dem Transkriptionsfaktor NF-κB identifiziert, die spezifischen Regulationsmechanismen konnten bisher allerdings nicht zufriedenstellend aufgeklärt werden. In dieser Arbeit wurde als eine neue mögliche Erklärung für die anti-inflammatorischen Eigenschaften des EP und weiterer α-oxo-Karbonsäureester die Inhibierung der Glyoxalase I (Glo-I) aufgezeigt. In vitro-Experimente zur Enzymaktivität belegten die Hemmung der Glo-I durch EP, während α-Hydroxy-Karbonsäureester wie L-Ethyllaktat (EL) keine inhibierenden Eigenschaften aufwiesen. Dennoch waren sowohl EP als auch EL und weitere Laktatester in der Lage, die LPS-induzierte Produktion von pro-inflammatorischen Zytokinen wie IL-1β, IL-6, IL-8 und TNF-α von humanen immunkompetenten Zellen zu supprimieren und die Expression von Immunrezeptoren wie HLA-DR, CD14 und CD91 zu modulieren. Somit konnten erstmals anti-inflammatorische Eigenschaften von Laktatestern nachgewiesen sowie eine Verbindung zwischen den Glyoxalase-Enzymen und dem Immunsystem etabliert werden. Diese und weitere Ergebnisse zur Einflussnahme der Karbonsäureester auf die Zellvitalität präsentieren das Glyoxalasesystem als mögliches Ziel neuer Therapiekonzepte für die Immunsuppression und bestätigen dessen Bedeutung für die Entwicklung von Anti-Tumor-Agenzien.

A asma é uma doença heterogênea caracterizada por um processo inflamatório crônico das vias aéreas inferiores que está associado ao desenvolvimento da hiperresponsividade brônquica e remodelamento da via aérea. Atualmente, a asma é considerada uma síndrome, ou ao menos uma doença com diversos fenótipos. Tradicionalmente, dois fenótipos são bem definidos pela clínica e exames subsidiários: asma alérgica e asma não alérgica. Eles são diferentes quanto á idade de início, apresentação clínica, história pessoal e familiar de atopia e resposta ao tratamento. Ao contrário da asma alérgica, cuja fisiopatologia está bem caracterizada, a etiologia e mecanismos envolvidos na asma não alérgica não estão bem elucidados. Algumas possibilidades incluem alergia desencadeada por antígenos desconhecidos (fungos), infecção persistente (Chlamydia trachomatis, Mycoplasma sp) e auto-imunidade. Estudos têm descrito em diferentes populações associações entre a asma e alelos/antígenos HLA classe I e II, mas os resultados têm sido inconclusivos. O objetivo deste estudo foi identificar possíveis associações do antígeno leucocitário humano (HLA) classe I (A, B, C) e II (DR, DQ, DP) em pacientes brasileiros com asma alérgica e não alérgica. Um total de 109 pacientes com o diagnóstico de asma (56 com asma alérgica e 53 com asma não alérgica) que estavam em acompanhamento no Serviço de Imunologia Clínica e Alergia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, e 297 controles (doadores falecidos de órgãos sólidos) tiveram seu sistema HLA classe I (A, B e C) e II (DR, DQ e DP) tipificado. Os pacientes também realizaram espirometria e coletaram sangue para a quantificação da imunoglobulina E (IgE) sérica total e nível sérico de eosinófilos. Além disso, foram avaliados quanto à IgE específica para aeroalergenos através do teste cutâneo de puntura e a pesquisa da IgE sérica específica (ImmunoCAP). O grupo com asma alérgica foi constituído por pacientes que apresentavam resultado positivo para a pesquisa da IgE específica em ambos teste cutâneo de puntura e na investigação in vitro. E o grupo com asma não alérgica apresentava resultados negativos nos dois testes. A comparação do HLA classe I nos grupos estudados identificou frequência significativamente maior do HLA-B*42 e HLA-C*17 no grupo com asma alérgica, enquanto o HLA-B*48 estava estatisticamente associado com o fenótipo não alérgico. Na análise do HLA classe II, o HLA-DPA1*03 e HLA-DPB1*105 apresentou associação com os pacientes com asma alérgica. Concluindo, o estudo observou diferentes associações dos alelos HLA classe I e II com asma alérgica e não alérgica na população brasileira, a qual é caracterizada pela diversidade de origens e miscigenação. Porém, a predisposição genética para asma é poligênica e novos estudos em grandes populações são necessários para confirmar a associação do HLA como fator protetor ou causador da doença / Asthma is a heterogeneous chronic inflammatory disease of lower airways associated with the development of bronchial hyperresponsiveness and airway remodeling. Currently, asthma is regarded as a syndrome or at least a disease with several phenotypes.Traditionally, two phenotypes of asthma have been defined according to clinical and laboratory features: allergic and non-allergic asthma. Each of them has distint age of onset, clinical presentation, personal and family history of allergy and response to therapy. In contrast to allergic asthma, which pathophysiology is well characterized, the etiology and mechanisms involved in non-allergic asthma remain unclear. Some possibilities include allergy triggered by unknow antigens (fungi), persistent infection (Chlamydia trachomatis, Mycoplasma sp) and autoimmunity. Studies have reported associations between asthma and HLA class I and II alleles/antigens in different populations, but the results have been inconclusive. The objective of this study was to identify possible associations of the human leukocyte antigens (HLA) class I (A, B and C) and II (DR, DQ and DP) in Brazilian patients with allergic and non-allergic asthma. A total of 109 patients with asthma (56 with allergic asthma and 53 with non-allergic asthma), who were being followed at the Service of Clinical Immunology and Allergy of the Hospital das Clínicas of the University of São Paulo Medical School, and 297 controls (deceased solid organ donors) had their HLA class I (A,B and C) and II (DR, DQ and DP) typing. Patients performed spirometry and had their blood drawn to measure total serum immunoglobulin E (IgE) levels and eosinophil count. Furthermore, they were assessed for specific IgE to aeroallergens with skin prick test and serum tests (ImmunoCAP). The allergic asthma group was composed of patient presenting positive results for specific IgE in both skin prick test and in vitro assay. And the non-allergic asthma group had negative results in both tests. There were significantly higher frequencies of HLA-B*42 and HLA-C*17 in the allergic asthma group, whereas the HLA-B*48 was associated with the non-allergic group. Regarding HLA class II analysis, HLA-DPA1*03 and HLA DPB1*105 were associated with allergic asthma patients. In conclusion, the study identified different associations of HLA class I and II with allergic and non-allergic asthma in the Brazilian population, which is characterized by diversity of origins and miscegenation. However, the genetic predisposition of asthma is polygenic and new studies on large populations are needed to confirm the role of HLA as a protective or predisposing factor of disease

A asma é uma doença heterogênea caracterizada por um processo inflamatório crônico das vias aéreas inferiores que está associado ao desenvolvimento da hiperresponsividade brônquica e remodelamento da via aérea. Atualmente, a asma é considerada uma síndrome, ou ao menos uma doença com diversos fenótipos. Tradicionalmente, dois fenótipos são bem definidos pela clínica e exames subsidiários: asma alérgica e asma não alérgica. Eles são diferentes quanto á idade de início, apresentação clínica, história pessoal e familiar de atopia e resposta ao tratamento. Ao contrário da asma alérgica, cuja fisiopatologia está bem caracterizada, a etiologia e mecanismos envolvidos na asma não alérgica não estão bem elucidados. Algumas possibilidades incluem alergia desencadeada por antígenos desconhecidos (fungos), infecção persistente (Chlamydia trachomatis, Mycoplasma sp) e auto-imunidade. Estudos têm descrito em diferentes populações associações entre a asma e alelos/antígenos HLA classe I e II, mas os resultados têm sido inconclusivos. O objetivo deste estudo foi identificar possíveis associações do antígeno leucocitário humano (HLA) classe I (A, B, C) e II (DR, DQ, DP) em pacientes brasileiros com asma alérgica e não alérgica. Um total de 109 pacientes com o diagnóstico de asma (56 com asma alérgica e 53 com asma não alérgica) que estavam em acompanhamento no Serviço de Imunologia Clínica e Alergia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, e 297 controles (doadores falecidos de órgãos sólidos) tiveram seu sistema HLA classe I (A, B e C) e II (DR, DQ e DP) tipificado. Os pacientes também realizaram espirometria e coletaram sangue para a quantificação da imunoglobulina E (IgE) sérica total e nível sérico de eosinófilos. Além disso, foram avaliados quanto à IgE específica para aeroalergenos através do teste cutâneo de puntura e a pesquisa da IgE sérica específica (ImmunoCAP). O grupo com asma alérgica foi constituído por pacientes que apresentavam resultado positivo para a pesquisa da IgE específica em ambos teste cutâneo de puntura e na investigação in vitro. E o grupo com asma não alérgica apresentava resultados negativos nos dois testes. A comparação do HLA classe I nos grupos estudados identificou frequência significativamente maior do HLA-B*42 e HLA-C*17 no grupo com asma alérgica, enquanto o HLA-B*48 estava estatisticamente associado com o fenótipo não alérgico. Na análise do HLA classe II, o HLA-DPA1*03 e HLA-DPB1*105 apresentou associação com os pacientes com asma alérgica. Concluindo, o estudo observou diferentes associações dos alelos HLA classe I e II com asma alérgica e não alérgica na população brasileira, a qual é caracterizada pela diversidade de origens e miscigenação. Porém, a predisposição genética para asma é poligênica e novos estudos em grandes populações são necessários para confirmar a associação do HLA como fator protetor ou causador da doença / Asthma is a heterogeneous chronic inflammatory disease of lower airways associated with the development of bronchial hyperresponsiveness and airway remodeling. Currently, asthma is regarded as a syndrome or at least a disease with several phenotypes.Traditionally, two phenotypes of asthma have been defined according to clinical and laboratory features: allergic and non-allergic asthma. Each of them has distint age of onset, clinical presentation, personal and family history of allergy and response to therapy. In contrast to allergic asthma, which pathophysiology is well characterized, the etiology and mechanisms involved in non-allergic asthma remain unclear. Some possibilities include allergy triggered by unknow antigens (fungi), persistent infection (Chlamydia trachomatis, Mycoplasma sp) and autoimmunity. Studies have reported associations between asthma and HLA class I and II alleles/antigens in different populations, but the results have been inconclusive. The objective of this study was to identify possible associations of the human leukocyte antigens (HLA) class I (A, B and C) and II (DR, DQ and DP) in Brazilian patients with allergic and non-allergic asthma. A total of 109 patients with asthma (56 with allergic asthma and 53 with non-allergic asthma), who were being followed at the Service of Clinical Immunology and Allergy of the Hospital das Clínicas of the University of São Paulo Medical School, and 297 controls (deceased solid organ donors) had their HLA class I (A,B and C) and II (DR, DQ and DP) typing. Patients performed spirometry and had their blood drawn to measure total serum immunoglobulin E (IgE) levels and eosinophil count. Furthermore, they were assessed for specific IgE to aeroallergens with skin prick test and serum tests (ImmunoCAP). The allergic asthma group was composed of patient presenting positive results for specific IgE in both skin prick test and in vitro assay. And the non-allergic asthma group had negative results in both tests. There were significantly higher frequencies of HLA-B*42 and HLA-C*17 in the allergic asthma group, whereas the HLA-B*48 was associated with the non-allergic group. Regarding HLA class II analysis, HLA-DPA1*03 and HLA DPB1*105 were associated with allergic asthma patients. In conclusion, the study identified different associations of HLA class I and II with allergic and non-allergic asthma in the Brazilian population, which is characterized by diversity of origins and miscegenation. However, the genetic predisposition of asthma is polygenic and new studies on large populations are needed to confirm the role of HLA as a protective or predisposing factor of disease

La chaîne invariante forme un complexe nonamérique avec les molécules classiques du CMH de classe II. HLA-DM et HLA-DO, des molécules non-classiques de classe II, sont aussi impliquées dans la présentation des peptides antigéniques aux lymphocytes T. Ces molécules chaperones de la présentation antigénique modulent la capacité d’une cellule à présenter des antigènes par les moloécules classiques du CMH de classe II. La régulation transcriptionnelle des molécules chaperones, tout comme celle des autres molécules du CMH de classe II, est assurée par le transactivateur CIITA. La molécule HLA-DR peut être régulée négativement de manière post-traductionnelle par ubiquitination grâce à l’enzyme E3 ubiquitine ligase MARCH1. Celle-ci est induite par l’interleukine-10 dans les monocytes. L’objectif de ce projet était de déterminer si l’ubiquitination par MARCH1 peut aussi réguler l’expression des molécules chaperones de la présentation antigénique. Les expériences furent réalisées dans le contexte de co-transfections en cellules HEK293T. L’expression des molécules fut évaluée par immunomarquages et cytométrie de flux. Il a été montré que l’isoforme p33 de la chaîne invariante est régulé négativement en présence de MARCH1 à partir de la surface cellulaire, causant ainsi sa dégradation. Tel que démontré par l’utilisation d’un mutant dépourvu de queue cytoplasmique, cette dernière région n’est pas indispensable à ce phénomène. Une hypothèse est qu’une molécule non-identifiée, associée à Ii, serait ubiquitinée par MARCH1, l’entraînant dans sa régulation négative. Il fut déterminer que cette molécule n’était pas CXCR2, un récepteur pouvant être impliqué, avec la chaîne invariante et CD44, en tant que récepteur de MIF (Macrophage Inhibitory Factor). Il fut aussi montré que HLA-DO peut être ciblé par MARCH1 mais ceci ne semble pas être un phénomène dominant; l’expression des complexes DO/DM n’étant pas affectée bien qu’ils entrent en interaction avec MARCH1. L’expression de HLA-DM n’est pas affectée par MARCH1. Il n’a toutefois pas été déterminé hors de tout doute si MARCH1 peut modifier DM; des résultats obtenus avec une queue cytoplasmique de DM possédant une lysine laissant suggérer qu’il est possible que MARCH1 interagisse avec DM. Dans l’ensemble, les travaux démontrent que l’ubiquitination par MARCH1 joue un rôle dans la régulation post-transcriptionnelle de la chaîne invariante p33 mais pas HLA-DO et HLA-DM. / The invariant chain, which form a nonameric complex with the classical MHC class II molecules. HLA-DM and HLA-DO (non-classical class II molecules) are involved in the presentation of antigens to T lymphocytes. The chaperons molecules of the antigenic presentation can modulate the capacity of the cells to present antigens. The transcriptional regulation of the chaperons and all of the other molecules linked to the MHC is assured by the CIITA transactivator. Little is know of the post-transcriptional mechanisms, other than the fact that HLA-DR molecule can be down-regulated by ubiquitination due to E3 ubiquitin ligase MARCH1. MARCH1 is induce by interleukin-10 in monocytes. The goal of this project is to figure out if ubiquitination by MARCH1 can also regulate the expression of the antigenic presentation chaperons. The experiences were performed in the context of co-transfections in HEK293T cells and the expression of the diverses molecules was evaluated by cell stainings and FACS analysis. The p33 isoform of the invariant chain was found to be down-regulated and degraded in the presence of MARCH1. The invariant chain cytoplasmic tail is not completely essential to this phenomenon; a non-identified molecule, associated with Ii, is probably ubiquitinated by MARCH1 and is then down-regulated, together with Ii. It was shown tha CXCR2, a reeptor involved with the invariant chain and CD44 in the reception of the MIF signal, is not that molecule. HLA-DO can ben targetd by MARCH1 but this does not seem to be a general phenomenon; the expression of the DO/DM complexes remaning unaffected even with the interaction of those complexes with MARCH1. Therefore, a certain protection seem to be provided by HLA-DM to HLA-DO. The expression of HLA-DM itself is not affected by the presence of MARCH1. However, it was not cleary demonstrated if MARCH1 can modify DM. Some results obtained with a cytoplasmic tail of DM comprising an additional lysine suggest that there is a possibility that MARCH1 interact with DM. Generally, the work presented here show that ubiquitination by MARCH1 is involved in post-transcriptionnal regulation of the p33 isoform of the invariant chain but not in the regulation of HLA-DO and HLA-DM.